Arvinas Inc. (ARVN)
NASDAQ: ARVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARVN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $423.03M
- EPS (TTM)
- -$0.08
- Dividend yield
- None
- 52-week range
- 6.33 – 14.51
- Day range
- 6.41 – 6.82
- Volume / Avg
- 1.11M / 848.52K
- Beta
- —
- Shares outstanding
- 65.49M
52-week range
ARVN stock today
Arvinas (ARVN) closed at $6.46 on Nov 20, down 4.15% (-$0.28), versus the S&P 500's 3.70% decline. Shares are 55.5% below their 52-week high of $14.51, set on Mar 10, 2026 and 2.1% above the 52-week low of $6.33, near the bottom of the past year's range. ARVN is down 45.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 43.9%.
Arvinas has posted a net loss over the last twelve months (EPS of -$0.08), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Arvinas
Company profileArvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Randy Teel Ph.D.
- Headquarters
- New Haven, CT
- Employees
- 246
- IPO year
- 2018
- Website
- arvinas.com
Financial highlights
Full financialsIn fiscal 2025, Arvinas generated $262.6 million in revenue, down 0.3% from fiscal 2024, its first annual decline since 2023. Arvinas reported a net loss of $80.8 million, compared with a loss of $198.9 million a year earlier. Operating margin was -45.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $262.60M | $263.40M | $78.50M | $131.40M | $53.60M |
| Growth | -0.30% | +235.54% | -40.26% | +145.15% | +106.95% |
| Net income | $-80.80M | $-198.90M | $-367.30M | $-282.50M | $-191.00M |
| EPS (diluted) | $-1.14 | $-2.77 | $-6.62 | $-5.31 | $-3.82 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$14.00+116.72%
- Strong buy 2
- Buy 5
- Hold 8
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.82 vs $-0.80
- Surprise
- -2.50%
ARVN news
All ARVN news- Arvinas to Present at Jefferies Global Healthcare ConferenceGlobeNewswire
- Arvinas (ARVN) Q3 2026 Earnings Call TranscriptNasdaq
- Arvinas, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNasdaqARVN, UHAL.B
- Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein DegradationGlobeNewswire
- Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026GlobeNewswire
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?NasdaqKYMR, ARVN, NRIX
- Roche Gets FDA Approval for Enspryng in Thyroid Eye DiseaseNasdaqHALO, ARVN, HOWL
Arvinas peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRTAProthena Corporation plc | 8.22 | -2.14% | $422.10M | vs ARVN |
| CRMDCorMedix Inc. | 5.27 | +3.74% | $419.16M | vs ARVN |
| OVIDOvid Therapeutics Inc. | 2.20 | -5.98% | $415.21M | vs ARVN |
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs ARVN |
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs ARVN |
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs ARVN |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs ARVN |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs ARVN |
Indexes, lists and sector
Arvinas stock FAQ
What is Arvinas's stock price today?
ARVN last traded at $6.46 as of Nov 20, 4:00 PM EST, down 4.15% on the day. Prices are delayed at least 15 minutes.
Who is Arvinas's CEO?
Dr. Randy Teel Ph.D. is the chief executive officer of Arvinas Inc., which has about 246 employees.
What is the ARVN 52-week high?
The 52-week high for ARVN is $14.51 and the 52-week low is $6.33. The stock is currently 55.5% below its high.